Session » Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Therapeutic Strategies, Biomarkers and Predictors of Outcomes in Rheumatoid Arthritis
-
Abstract Number: 2471
Effect of Teriparatide in Patients with Osteoporosis and Rheumatoid Arthritis
-
Abstract Number: 2472
The First, Multicenter, Double-Blind, Randomized, Parallel-Group Study of Certolizumab Pegol in Early Rheumatoid Arthritis Demonstrates Inhibition of Joint Damage Progression
-
Abstract Number: 2474
Efficacy and Tolerability of Subcutaneous Methotrexate for Inflammatory Arthritis: A Retrospective Observational Cohort Study
-
Abstract Number: 2475
Multiple Approaches for Implementation of Long-Term Efficacy: Interpretation of Certolizumab Pegol Data in Rheumatoid Arthritis Case Study
-
Abstract Number: 2477
Integrating Treatment Goals of Physicians, Patients, and Payers during Treatment with Golimumab in Patients with Rheumatoid Arthritis
-
Abstract Number: 2478
Analysis of the Clinical Sustained Response after Retreatment with a Lower Dose of Rituximab in Patients with Chronic Inflammatory Arthropathies
-
Abstract Number: 2479
Utility of Adjustment of Administration Interval in Tocilizumab in Rheumatoid Arthritis
-
Abstract Number: 2480
Is there a Difference in the Effectiveness in the Treatment of Rheumatoid Arthritis with Rituximab when Using a Dose of 1 or 2 Grams per Cycle? a Systematic Review
-
Abstract Number: 2482
Use of Biologic Therapy As Monotherapy in Patients with Rheumatoid Arthritis
-
Abstract Number: 2483
Treatment Adjustment Strategy after Achieving Remission or Low Disease Activity in Rheumatoid Arthritis : A Systematic Review and Meta-Analysis
-
Abstract Number: 2484
Adding an Initial Six-Month Course of Infliximab to an Active Combination Treatment Is Cost Saving in Working-Aged Early Rheumatoid Arthritis Patients
-
Abstract Number: 2485
Predictors of Drug-Free Remission Following Treatment with Abatacept (in Combination with Methotrexate or as Monotherapy) in Early Rheumatoid Arthritis
-
Abstract Number: 2487
Effects of Tofacitinib on Health Care Resource Utilization and Work Productivity in US Patients with Rheumatoid Arthritis
-
Abstract Number: 2488
Relationship Between Different Clinical Measurements and Patient-Reported Outcomes
-
Abstract Number: 2489
Analysis of Early Neutropenia, Clinical Response, and Serious Infection Events in Patients Receiving Tofacitinib for Rheumatoid Arthritis
-
Abstract Number: 2490
Assessment of Structural Benefits of SC Abatacept Using MRI in Patients with RA Who Have Failed 1 or 2 TNFs and Correlated with Clinical Outcomes As Measured By DAS28(ESR)
-
Abstract Number: 2491
Prognostic Factors for IV Abatacept Retention in Patients Who Have Received at Least One Prior Biologic Agent: 2-Year Results from a Prospective, International, Real-World Study
-
Abstract Number: 2493
Prediction of Remission and Low Disease Activity in DMARD-Refractory Patients with RA Treated with Golimumab
-
Abstract Number: 2494
Persistence on Single Disease Modifying Anti-Rheumatic Drug Therapy in US Veterans with Rheumatoid Arthritis Is Extremely Rare
-
Abstract Number: 2495
Impact of Golimumab on Physical Function and Employability of Patients with Rheumatoid Arthritis: 5-Year Data from 3 Phase III Clinical Trials
-
Abstract Number: 2498
Characteristics of Responding Versus Non-Responding Moderate Rheumatoid Arthritis Patients Treated with Etanercept Plus Methotrexate
-
Abstract Number: 2499
Early Response Indicator early Predicts Clinical Response to Certolizumab in Rheumatoid Arthritis Patients
-
Abstract Number: 2500
Genetic Variation in the TLR5 Locus Is Associated with Anti-TNF Response Among Rheumatoid Arthritis Patients
-
Abstract Number: 2501
Indirect Comparison of Tocilizumab and Tofacitinib in Patients with Rheumatoid Arthritis
-
Abstract Number: 2502
Ten Year Follow-up Results of Four Dynamic Treat to Target Strategies in Patients with ACPA Negative Rheumatoid Arthritis
-
Abstract Number: 2503
Early Response to Full-Dose Etanercept-Plus-Methotrexate Induction Therapy Predicts Sustained Remission with Reduced-Dose Combination Therapy in Early Rheumatoid Arthritis Patients
-
Abstract Number: 2504
Impact of Concomitant Methotrexate on the Enhanced Clinical Efficacy of Abatacept after 24 Weeks in Rheumatoid Arthritis Patients
-
Abstract Number: 2505
Long-Term Treatment with Tocilizumab (TCZ) Strongly Suppresses Joint Destruction in Biologic-naïve Patients with Rheumatoid Arthritis (RA) Regardless of Inflammation Status
-
Abstract Number: 2507
Is There an Autoinflammatory Component in Rheumatoid Arthritis Associated with Better Response to Anakinra (Kineret®)?
-
Abstract Number: 2508
Tocilizumab Serum Trough Levels and Its Relationship with Disease Activity and Drug Dosage in Rheumatoid Arthritis Patients
-
Abstract Number: 2509
ADAM-10 As a Tocilizumab Treatment Predictive Factor in Rheumatoid Arthritis
-
Abstract Number: 2510
Good Response to Methotrexate (MTX) and/or MTX Plus Adallimumab (ADA): 3 Yrs Study Results in Patients with Rheumatoid Arthritis (RA)
-
Abstract Number: 2511
Predictors of Discontinuation of Biologic DMARD Therapy Due to Remission in Patients with Rheumatoid Arthritis in a National Registry
-
Abstract Number: 2512
Golimumab Therapy Retention Rates in Patients with Rheumatoid Arthritis and Seronegative Spondyloarthritis: Data from the Italian Lorhen Registry
-
Abstract Number: 2513
The Monitoring of Infliximab Levels at Early Stages Can Predict the Development of Anti-Infliximab Antibodies in a Cohort of Rheumatoid Arthritis Patients Treated with Infliximab
-
Abstract Number: 2514
Biological Treatment for Rheumatoid Arthritis (RA): A Fifteen Years Multicentric Overview
-
Abstract Number: 2515
Serum Survivin in Early Rheumatoid Arthritis
-
Abstract Number: 2516
Reasons and Risk Factor for Discontinuation of Biologic Agents in Rheumatoid Arthritis Patients
-
Abstract Number: 2517
Long-Term Clinical, Structural, and Functional Consequences of Not Adopting Treatment in MTX Suboptimal Responders
-
Abstract Number: 2518
What Is the Level of Agreement Between Disease Activity Indices and Response Criteria Among Rheumatoid Arthritis Patients Treated with TNF Inhibitors?
-
Abstract Number: 2519
Are Patients with Rheumatoid Arthritis Initiating a TNF Biologic Comparable to Patients Initiating a Non TNF?
-
Abstract Number: 2520
Patient, Genetic and Disease Factors Influence the Response to the Disease Modifying Anti-Rheumatic Drug Leflunomide
-
Abstract Number: 2521
Analysis on Predictors for Long-Term Clinical Efficacies of Golimumab in Patients with Rheumatoid Arthritis
-
Abstract Number: 2522
Effect of Infliximab Dose Increase in Rheumatoid Arthritis at Different Trough Concentrations
-
Abstract Number: 2523
Are Biologic Agents Effective on the Treatment of Secondary Amyloidosis: A Multicenter Report on Turkish Rheumatoid Arthritis and Ankylosing Spondylitis Patients
-
Abstract Number: 2524
Smoking and Response to Rituximab in Anti-CCP Positive and Negative Rheumatoid Arthritis – Results from an International European Collaboration
-
Abstract Number: 2525
Infliximab Versus Conventional Combination Treatment and Work Loss in Early RA over 7 Years: A Randomized Trial
-
Abstract Number: 2526
Efficacy of Biological Therapies in Rheumatoid Arthritis: Graphical Modeling of DAS28 Components’ Evolution over Time
-
Abstract Number: 2527
The Effect of Biological Agents on Work in Patients with Chronic Inflammatory Arthritides: A Meta-Analysis of Randomized Controlled Trials and Controlled Cohorts
-
Abstract Number: 2528
Efficacy Meta-Analysis of Randomized Controlled Trials (RCTs) of Biologics in Methotrexate-Naive Patients with Early Rheumatoid Arthritis